Primer: Mabpharm (2181 HK) - Aug 2026
Mabpharm has successfully transitioned from a development-stage company to a commercial entity, achieving profitability in the most recent...
92 Views
𝛼SK or SearchENTITY
Mabpharm (2181 HK)
Mabpharm (2181 HK)
23
Analysis
Industrials • Hong Kong
Mabpharm is a biopharmaceutical company specializing in the research, development, and manufacturing of monoclonal antibody drugs and biosimilars for cancer and autoimmune diseases. Its core products include CMAB009 Enlito, CMAB007 AomaiShu, and CMAB008 Leiting, which treat various conditions such as colorectal cancer, asthma, and rheumatoid arthritis. The company was founded in 2009 and is headquartered in Taizhou, Jiangsu, PRC.
morex